JP2011528352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528352A5 JP2011528352A5 JP2011518733A JP2011518733A JP2011528352A5 JP 2011528352 A5 JP2011528352 A5 JP 2011528352A5 JP 2011518733 A JP2011518733 A JP 2011518733A JP 2011518733 A JP2011518733 A JP 2011518733A JP 2011528352 A5 JP2011528352 A5 JP 2011528352A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- secreted protein
- isolated
- purified
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002987 choroid plexus Anatomy 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 230000001225 therapeutic effect Effects 0.000 claims 14
- 239000003636 conditioned culture medium Substances 0.000 claims 8
- -1 PDGF Proteins 0.000 claims 6
- 206010052428 Wound Diseases 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 3
- 102100031168 CCN family member 2 Human genes 0.000 claims 3
- 108050006947 CXC Chemokine Proteins 0.000 claims 3
- 102000019388 CXC chemokine Human genes 0.000 claims 3
- 102000015833 Cystatin Human genes 0.000 claims 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 3
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 claims 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 3
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims 3
- 108091058560 IL8 Proteins 0.000 claims 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 3
- 102000004890 Interleukin-8 Human genes 0.000 claims 3
- 108090001007 Interleukin-8 Proteins 0.000 claims 3
- 102000007547 Laminin Human genes 0.000 claims 3
- 108010085895 Laminin Proteins 0.000 claims 3
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 3
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims 3
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims 3
- 108010071690 Prealbumin Proteins 0.000 claims 3
- 102000005157 Somatostatin Human genes 0.000 claims 3
- 108010056088 Somatostatin Proteins 0.000 claims 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 3
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims 3
- 102000009190 Transthyretin Human genes 0.000 claims 3
- 102000009137 Tropomodulin-3 Human genes 0.000 claims 3
- 108050000002 Tropomodulin-3 Proteins 0.000 claims 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 3
- 108010001122 alpha(2)-microglobulin Proteins 0.000 claims 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 3
- 108050004038 cystatin Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 210000002744 extracellular matrix Anatomy 0.000 claims 3
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims 3
- 229930002330 retinoic acid Natural products 0.000 claims 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 3
- 229960000553 somatostatin Drugs 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 229960001727 tretinoin Drugs 0.000 claims 3
- 230000029663 wound healing Effects 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 206010072170 Skin wound Diseases 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000004983 pleiotropic effect Effects 0.000 claims 2
- 208000025978 Athletic injury Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 206010018852 Haematoma Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 206010041738 Sports injury Diseases 0.000 claims 1
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000002730 additional effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 229960001810 meprednisone Drugs 0.000 claims 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13502608P | 2008-07-15 | 2008-07-15 | |
| US61/135,026 | 2008-07-15 | ||
| PCT/US2009/004129 WO2010008573A2 (en) | 2008-07-15 | 2009-07-15 | Wound healing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016002681A Division JP6309033B2 (ja) | 2008-07-15 | 2016-01-08 | 創傷の治癒 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011528352A JP2011528352A (ja) | 2011-11-17 |
| JP2011528352A5 true JP2011528352A5 (https=) | 2012-09-13 |
Family
ID=41550919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518733A Pending JP2011528352A (ja) | 2008-07-15 | 2009-07-15 | 創傷の治癒 |
| JP2016002681A Active JP6309033B2 (ja) | 2008-07-15 | 2016-01-08 | 創傷の治癒 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016002681A Active JP6309033B2 (ja) | 2008-07-15 | 2016-01-08 | 創傷の治癒 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110177025A1 (https=) |
| EP (1) | EP2318034B1 (https=) |
| JP (2) | JP2011528352A (https=) |
| AU (3) | AU2009271598A1 (https=) |
| NZ (1) | NZ591037A (https=) |
| WO (1) | WO2010008573A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120101021A1 (en) * | 2009-02-06 | 2012-04-26 | Surendra Sharma | Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy |
| WO2012126369A1 (zh) * | 2011-03-22 | 2012-09-27 | 北京三诺佳邑生物技术有限责任公司 | 核苷酸、包括其的重组载体、细胞、组合物及它们的应用 |
| US20130123647A1 (en) | 2011-05-03 | 2013-05-16 | The Research Foundation Of State University Of New York | Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections |
| TWI649095B (zh) * | 2012-02-10 | 2019-02-01 | 捷百克股份有限公司 | 以非人類幹細胞之培養上清液為起始材料之化妝品或皮膚再生促進劑、及蛋白質之離子導入法 |
| EP2687224A1 (en) * | 2012-07-19 | 2014-01-22 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | Medicament for wound treatment |
| US20140088402A1 (en) | 2012-09-25 | 2014-03-27 | Innovative Therapies, Inc. | Wound measurement on smart phones |
| CN106906180A (zh) * | 2016-12-28 | 2017-06-30 | 里程 | 一种具有生物活化作用的复合添加剂及其制备方法和用途 |
| CN111050763B (zh) * | 2017-12-26 | 2024-10-11 | 福冈大太朗 | 用于増毛、头皮或皮肤的改质、创伤治愈、骨形成促进或毛发的改质的药物组合物 |
| CN113274538B (zh) * | 2021-05-28 | 2022-09-06 | 中国科学院过程工程研究所 | 一种具有创面主动修复功能的bFGF缓释纳米敷料及其制备方法和应用 |
| CN114381421B (zh) * | 2022-02-09 | 2023-08-15 | 河北医科大学 | 溶菌酶诱导的小鼠血管平滑肌细胞炎症模型及其建立方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8011A (en) * | 1851-04-01 | Improvement in blasti ng rocks | ||
| US4021A (en) * | 1845-05-01 | Isaac l | ||
| US20020127594A1 (en) * | 2000-06-22 | 2002-09-12 | Gearing David P. | Don-1 gene and polypeptides and uses therefor |
| US20050265977A1 (en) * | 1999-04-30 | 2005-12-01 | Elliott Robert B | Xenotransplant for CNS therapy |
| US20040213768A1 (en) * | 1999-04-30 | 2004-10-28 | Elliott Robert Bartlett | Preparation for biotransplantation and xenotransplantion and uses thereof |
| EP1176970B1 (en) * | 1999-04-30 | 2010-05-19 | NeurotrophinCell Pty Ltd | Xenotransplant for cns therapy |
| WO2003065999A2 (en) * | 2002-02-08 | 2003-08-14 | University Of South Florida | Proliferated cell lines and uses thereof |
| US20040009915A1 (en) * | 2002-03-06 | 2004-01-15 | Han Chang | Polynucleotides encoding a novel intracellular chloride channel-related polypeptide |
| NZ536009A (en) * | 2005-04-18 | 2007-01-26 | Neurotrophincell Pty Ltd | Choroid plexus preparation and uses thereof |
| NZ540597A (en) * | 2005-06-08 | 2007-02-23 | Neurotrophincell Pty Ltd | A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells |
| WO2007028053A2 (en) * | 2005-09-02 | 2007-03-08 | X-Cell Medical Incorporated | Methods of treating and preventing cardiac disorders |
| US20080119909A1 (en) * | 2006-11-21 | 2008-05-22 | Neurotrophincell Pty Limited | Cell implantation to prevent and/or treat hearing loss |
| ES2324192B1 (es) * | 2008-01-30 | 2010-06-17 | PUIG BEAUTY & FASHION GROUP, S.L. | Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas. |
-
2009
- 2009-07-15 US US13/054,428 patent/US20110177025A1/en not_active Abandoned
- 2009-07-15 NZ NZ591037A patent/NZ591037A/xx unknown
- 2009-07-15 JP JP2011518733A patent/JP2011528352A/ja active Pending
- 2009-07-15 AU AU2009271598A patent/AU2009271598A1/en not_active Abandoned
- 2009-07-15 WO PCT/US2009/004129 patent/WO2010008573A2/en not_active Ceased
- 2009-07-15 EP EP09798310.0A patent/EP2318034B1/en active Active
-
2015
- 2015-09-10 US US14/850,755 patent/US20180008644A1/en not_active Abandoned
-
2016
- 2016-01-08 JP JP2016002681A patent/JP6309033B2/ja active Active
- 2016-05-05 AU AU2016202913A patent/AU2016202913A1/en not_active Abandoned
-
2018
- 2018-03-16 AU AU2018201925A patent/AU2018201925C1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528352A5 (https=) | ||
| US12005084B2 (en) | Composition derived from mammalian umbilical cord and Whartons jelly for use in therapeutic and regenerative applications | |
| JP6309033B2 (ja) | 創傷の治癒 | |
| US9402881B2 (en) | Tissue regeneration and wound treatment methods with platelet derived compositions | |
| KR20080100425A (ko) | 조절된 혈액 조성물 및 이의 생산 방법 | |
| US11813309B2 (en) | Method of alleviating chronic wounds | |
| Louzada et al. | Granulocyte-colony stimulating factor treatment of chronic myocardial infarction | |
| Mzezewa et al. | A prospective double blind randomized study comparing the need for blood transfusion with terlipressin or a placebo during early excision and grafting of burns | |
| CN106420779B (zh) | 一种促进伤口愈合的组合物 | |
| JP4790195B2 (ja) | 組織再生剤 | |
| CA2578212A1 (en) | Methods for promoting wound healing | |
| CN1250287C (zh) | 一种重组腺病毒在脑缺血、创伤修复和组织粘连治疗中的应用 | |
| US20230398195A1 (en) | Composition derived from mammalian umbilical cord and whartons jelly for use in therapeutic and regenerative applications | |
| CN120661514B (zh) | Jak抑制剂新应用及促进皮肤牵张再生的药物 | |
| WO2008073653A2 (en) | Il- 17b for use in wound healing | |
| CN1956705A (zh) | 用于治疗局部细菌感染和细菌性相关疾病的集落刺激因子组合物 | |
| Cheng et al. | Effects of the Zhikang capsule on healing of the flap after radical breast cancer surgery | |
| CN120168610A (zh) | 一种白细胞介素-13在促进肌肉损伤后修复中的应用 | |
| CN113797316A (zh) | 用于修复组织损伤的组合物及其制备方法和应用 | |
| CN116196394A (zh) | 重组人Matrilin-3蛋白在制备治疗脑血管疾病的药物中的应用 | |
| US20190321412A1 (en) | Methods and compositions using dehydrated human amnion/chorion membrane allograft and amnionic membrane allograft suspensions for the treatment of hair loss | |
| CN121943970A (zh) | 蚕蛹在制备防治呼吸暂停综合征并发症的药物及食品中的用途 | |
| TW202415401A (zh) | 臺灣白及（Ｂｌｅｔｉｌｌａ ｆｏｒｍｏｓａｎａ （Ｈａｙａｔａ） Ｓｃｈｌｔｒ．）萃取物用於製備促進慢性傷口癒合的醫藥組合物之用途 | |
| CN114146095A (zh) | 用于组织损伤修复的组合物及其制备方法和用途 | |
| Arany et al. | 14 Multiphasic Roles for TGF-Beta in Scarring |